Novo Nordisk A/S
Clinical trials sponsored by Novo Nordisk A/S, explained in plain language.
Global healthcare company specializing in diabetes and obesity care.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New weekly shot could protect kidneys in people with obesity Results expected Sep 2026 (estimated) May already have reported ↗
- New combo shot aims to tame type 1 diabetes Results expected Sep 2026 (estimated) May already have reported ↗
- Researchers survey Weight-Loss drug users to understand Real-World experiences Results expected Sep 2026 (estimated)
- Liver scan changes may foretell deadly complications Results expected Sep 2026 (estimated)
- New drug aims to ease heart failure symptoms in inflamed patients Results expected Oct 2026 (estimated)
-
Could a monthly shot cut heart failure deaths? major trial underway
Disease control Stopped earlyThis study tests whether a monthly injection called ziltivekimab can reduce heart failure-related deaths, hospitalizations, and urgent visits in people with heart failure and signs of inflammation. About 5,600 participants will receive either the drug or a placebo for up to 4 yea…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Obesity drug study ends early, but Real-World data may still help
Disease control Stopped earlyThis study aimed to see how well semaglutide works for weight loss in everyday medical practice, outside of a strict research setting. It involved 100 adults with obesity who were already planning to take the drug. The study was stopped early, so results are limited, but it may s…
Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Why do some kids respond to growth hormone? scientists look to genetics
Knowledge-focused Stopped earlyThis study looked at children with idiopathic short stature (short stature with no known cause) who had already received growth hormone therapy for at least a year. Researchers compared the genetic profiles of those who responded well to treatment versus those who did not. The go…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC